LGM
SWTX

Logos Global Management’s SpringWorks Therapeutics SWTX Stock Holding History

Logos Global Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-110,000
Closed -$4.62M – 59
2020
Q2 		$4.62M Buy
+110,000
New +$3.91M 0.92% 33
2020
Q1 		– Sell
-134,397
Closed -$5.17M – 53
2019
Q4 		$5.17M Buy
+134,397
New +$3.15M 1.28% 22

Other funds holding SWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Logos Global Management's SWTX Position: Q3 2020 in Review

Logos Global Management sold out of SpringWorks Therapeutics (SWTX) in Q3 2020, closing a stake of 110,000 shares — an estimated $4.62M sold.

Logos Global Management first reported a position in SWTX in Q4 2019 and held it in 2 quarters. The position peaked at $5.17M in Q4 2019. 92 funds tracked by Wall St. Rank hold SWTX as of Q3 2020.

  • Logos Global Management reported no remaining SpringWorks Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Logos Global Management sold 110,000 SpringWorks Therapeutics shares in Q3 2020, an estimated $4.62M.
  • Logos Global Management first reported a position in SpringWorks Therapeutics in Q4 2019 and held it in 2 quarters.
  • Logos Global Management's SpringWorks Therapeutics position peaked at $5.17M in Q4 2019.
  • 92 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2020.

Based on Logos Global Management's 13F filing for Q3 2020, filed 16 Nov 2020.